Dean's List: New Funding Awards
Dean's List:
New Funding Awards
Notable and novel scientific awards to celebrate.
December 2025New Federal Awards | ||||
| Craig Morita | Internal Medicine | DoD CDMRP 2 years | Targeting Delta-like Ligand 3 with Gamma Delta T Cell Engagers to Treat Neuroendocrine Prostate Cancer | |
| Other Awards | ||||
| Prajwal Dhakal | Internal Medicine | AstraZeneca Pharmaceuticals LP | AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants with Acute Lymphoblas | |
| Naomi Fei | Internal Medicine | Merck Sharp & Dohme LLC | MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advan | |
| Anthony Fischer | Pediatrics | Cystic Fibrosis Foundation | Repurposing Pancreatic Enzymes For Treatment of Meconium Ileus | |
| Tara Graff | Internal Medicine | Celgene Corporation | Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma | |
| Marlan Hansen | Otolaryngology | Sound Pharmaceuticals Incorporated | SPI-1005 IN ADULTS RECEIVING A COCHLEAR IMPLANT | |
| Seema Harichand-Herdt | Internal Medicine | AstraZeneca LP | Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) Sponsor | |
| Lama Noureddine | Internal Medicine | Vertex Pharmaceuticals, Inc. | VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants | |
| Kristin Plichta | Radiation Oncology | Novartis Pharmaceuticals Corporation | AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer | |
| Andrea Swenson | Neurology | Arthex Biotech, S.L. | Intravenous Administration of ATX-01 In Male and Female Participants aged 18 to 64 with Classic Myotonic Dystrophy Type 1 (DM1) | |
| Hanna Zembrzuska | Internal Medicine | Argenx BV | Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogren's Disease | |
| Hanna Zembrzuska | Internal Medicine | Argenx BV | AlloNK, an allogeneic cord blood-derived NK cell therapy, in combination with rituximab in relapsing forms of B-cell dependent rheumatologic diseases | |
October 2025New Federal Awards | ||||
| Santosh Kumar | Internal Medicine | NIH R21 2 years | CFTR and Vascular endothelial function | |
| Other Awards | ||||
| Bruce Gantz | Otolaryngology | Cochlear Americas | A pivotal, prospective, multicentre, single-arm study evaluating the safety and efficacy of a dexamethasone eluting Slim Modiolar Electrode array (EA32) | |
| Yusuf Menda | Radiology | Fusion Pharmaceuticals, Inc. | A phase 2/3, randomized, open-label, multicenter Study to evaluate the safety and efficacy of FPI-2265 (225Ac-PSMA-I&T) in patients with PSMA-positive Metastatic castration-resistant prostate Cancer (MCRPC), previously treated with 177Lu-PSMA Radioligand therapy (RLT) | |
September 2025New Federal Awards | ||||
| Anil Chauhan | Internal Medicine | NIH R01 4 years | Platelet function abnormalities underlying bleeding in a connective tissue disorder-the Ehlers-Danlos syndrome | |
| Alex Dou | Molecular Physiology & Biophys | NIH F30 4 years | Dissecting the molecular mechanism of the cardiac fight-or-flight response via real-time light-controlled phosphorylation of Rad | |
| Ying Hsu | Ophthalmology & Visual Sci | NIH K99 1 year | Immune activation and subject-specific risk in ocular gene therapies | |
| Long-Sheng Song | Internal Medicine | NIH R01 4 years | Junctophilin-2 in Cardiac Fibroblasts | |
| Competitive Renewal | ||||
| Kevin Campbell | Molecular Physiology & Biophys | NIH P50 5 years | Muscular Dystrophy Specialized Research Center | |
| Aliye Uc | Pediatrics | NIH U01 5 years | INSPPIRE: Using the natural history of pediatric chronic pancreatitis to identify disease predictors and design therapies | |
| Jan Wessel | Psychological & Brain Sciences | NIH R01 5 years | Resolving the paradoxical effects of subthalamic deep-brain stimulation on inhibitory motor control | |
August 2025New Federal Awards | ||||
Barry London, (MPI) Bryan Allen, (Contact PI) | NIH R21 2 years | Using a Superoxide Dismutase Mimetic to Mitigate Age-Associated, Radiation-Induced Cardiopulmonary Damage: Investigating the Role of Nitro-Oxidative Signaling and Mitochondrial Metabolism | ||
| Jennifer Bermick | Pediatrics | NIH R56 1 year | Understanding how perinatal inflammation directs trained immunity in offspring | |
| Jonathon Bernardi | Microbiology | NIH F31 2 years | Metabolic regulation of anti-malarial humoral immunity | |
| Anil Chauhan | Internal Medicine | NIH R01 4 years | Regulating Cellular Metabolism and Energy Flow to Target Thrombosis | |
| Christina Cho | Internal Medicine | DoD 2 years | Spatial Proteogenomics to Identify Novel Prognostic and Predictive Biomarkers in Melanoma | |
| Anthony Fischer | Pediatrics | NIH R03 2 years | Environmental acquisition of ST398 Staphylococcus aureus by patients with chronic respiratory disease | |
| Laura Frey Law (MPI) Karim Abdel-Malek | DoD 2 years | Iowa-Soldier Training & Readiness through Kinetic Evaluation (I-STRiKE) | ||
| Michelle Higgins | Otolaryngology | NSF 1 year | I-Corps: Translation Potential of Surgical Simulation for Ear and Hearing Related Surgical Training | |
| Rainbo Hultman (Contact PI) Hanna Stevens (MPI) | NIH R01 5 years | Networking the parental brain: Transformation of brain-wide electrical networks | ||
| Emily Liu | Anatomy | NIH F31 3 years | The role of TGF-beta signaling in cell-cell interactions in the pathogenesis of lymphangioleiomyomatosis | |
| Nicholas Mohr (Contact PI) Brett Faine (MPI) Heather Reisinger (MPI) | NIH R01 4 years | Characterizing a High-Reliability Implementation Program for Sepsis: Sepsis Tools AND Accurate Reporting of Outcome Differences (STANDARD) Study | ||
| Dawn Quelle (Contact PI) James Howe (MPI) Yusuf Menda (MPI) | NIH P50 5 years | Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer | ||
| Jon Resch | Neuroscience & Pharmacology | NIH R01 5 years | NTSHSD2 neuron activity: regulation by aldosterone and afferent control | |
| David Stoltz | Internal Medicine | NIH P01 5 years | Pathogenesis and Therapeutic Approaches in Primary Ciliary Dyskinesia | |
| Ling Yang (Contact PI) Long-Sheng Song (MPI) | NIH R01 4 years | Shaping Cardiac Immuno-metabolic Homeostasis by the Lysosome | ||
| Competitive Renewal | ||||
| Amy Ryan | Anatomy | NIH P30 5 years | Precision Medicine Center for Cystic Fibrosis | |
| Mary Weber | Microbiology | NIH R01 5 years | Functional characterization of Chlamydia trachomatis inclusion membrane proteins and their role in subversion of the host vesicular trafficking | |
July 2025New Federal Awards | ||||
| Anil Chauhan | Internal Medicine | NIH R01 4 years | Metabolic reprogramming in experimental deep vein thrombosis and resolution | |
| Vikas Dudeja | Surgery | DoD, CDMRP 5 years | Evaluating Pirfenidone as a Novel Treatment for Chronic Pancreatitis | |
| Mariah Hassert | Pathology | NIH K99 2 years | Hemozoin and liver stage malaria vaccine efficacy | |
| Dakota Jones | Anatomy and Cell Biology | NIH R00 3 years | Mesenchymal cell plasticity and signaling in lung regeneration | |
| Colin Kenny | Surgery | NIH R03 2 years | Establishing an in-vivo Sleeping-Beauty Screen to Identify and Characterize Novel Drivers of Melanomagenesis in a Nevi-Prone Zebrafish Model | |
| Toshihiro Kitamoto | Anesthesia | NIH R21 2 years | Protective roles of the lithium-inducible SLC6 transporter in lithium's adverse effects: Insights from Drosophila genetics | |
| Alison Lynch | Psychiatry | US Department of Health & Human Services, Health Resources & Services Administration 5 years | University of Iowa Addiction Medicine Fellowship (UI AMF) | |
| Amy Ryan | Anatomy and Cell Biology | NSF 1 year | Conference: Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases | |
| Shailesh Shahi | Pathology | DoD, CDMRP 3 years | Impact of Obesity-Driven Gut Microbiota Alterations on Multiple Sclerosis Severity | |
| Susan Shen | Psychiatry | NIH DP1 5 years | Molecular and Cellular Subtyping of Response to Drugs of Abuse in Co-morbid Psychiatric Disorders | |
| Maria Spies | Biochemistry and Molecular Biology | NIH R01 11 years | The role of human RAD52 protein in genome stability | |
| Li Wu | Microbiology | NIH 5 years | How SAMHD1 regulates HIV-1 innate immunity and viral gene expression | |
| Competitive Renewal | ||||
| Damian Krysan | Pediatrics | NIH R01 | Genetic and mechanistic analysis of carbon dioxide tolerance in Cryptococcus pathogenesis | |
| Scott Moye-Rowley | Molecular Physiology & Biophysics | NIH R01 5 years | Elevated gene transcription of the cyp51A gene is essential for azole drug resistance in Aspergillus fumigatus | |
| Erin Crocker | Psychiatry | Iowa Department of Health and Human Services 3 years | Rural Psychiatry Residency Training Program | |
| Other Awards | ||||
| Mark Burkard | Internal Medicine | Scorpion Therapeutics, Inc. 3 years | First-in-Human Study of STX-478, a Mutant-Selective PI3Ka; Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | |
| Adriana Della Pietra | Molecular Physiology and Biophysics | King's College London 2 years | Combinatorial Use Of Cannabidiol And The Serine Hydrolase Inhibitor AKU-005 To Enhance Endocannabinoids For Treatment Of Migraine | |
| Tara Graff | Internal Medicine | BeiGene USA, Inc. 4 years | Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies | |
| Tara Graff | Internal Medicine | Genentech, Inc 2 years | Adding Venetoclax to patients on Covalent BTKI for 1L CLL can achieve deep durable remissions (by uMR 10-4) to allow off-treatment period. | |
| Andrew Groves | Pediatrics | Day One Biopharmaceuticals, Inc. 3 years | DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy | |
| Parren McNeely | Radiology | Radionetics Oncology, Inc. 3 years | 68Ga-R10602 designed to characterize its safety, biodistribution, tumor detection capability, radiation dosimetry and pharmacokinetics (PK) in study participants with locoregionally recurrent or metastatic hormone receptor-positive breast cancer | |
| Robert Piper | Anatomy and Cell Biology | University of Alabama at Birmingham 1 year | Engelhardt C06 Architectural Plans | |
| Steven Polyak | Internal Medicine | Sanofi US Services, Inc. 3 years | SAR442970 in adults with moderate to severe Crohn's disease | |
| Steven Polyak | Internal Medicine | Sanofi US Services, Inc. 3 years | SAR442970 in adult participants with moderate to severe ulcerative colitis | |
| Matthew Potthoff | Neuroscience & Pharmacology | Oklahoma University Health Science Center 1 year | Dr. Matt Potthoff's lab & student costs through June 30, 2025 | |
| Michael Tansey | Pediatrics | BioMarin Pharmaceutical, Inc. 3 years | Vosoritide in Children with Idiopathic Short Stature | |
| Hanna Zembrzuska | Internal Medicine | Resolve Therapeutics, LLC 3 years | Intravenous RSLV-132 in Participants with Sjogren's Syndrome (SS) with Moderate to Severe Symptom Burden | |
June 2025New Federal Awards | ||||
| Alexander Boyden | Pathology | NIH R21 2 years | Gamma herpesvirus impact on required B cell:CD4 T interactions in a B cell-dependent, antibody-independent mouse model of multiple sclerosis | |
| Alexander Claussen | Otolaryngology | NIH K08 5 years | Defining the Mechanisms and Clinical Impact of Neo-ossification after Cochlear Implantation | |
| Karen Cyndari | Emergency Medicine | NIH K08 5 years | Synovium Immunoprivilege and the Modulation of Resident Synovial Macrophage Functions in Lyme Arthritis | |
| Alexander Kleinpeter | Microbiology | NIH R21 2 years | Elucidating the role of IP6 in HIV-1 assembly, maturation, and infection. | |
| Brajesh Singh | Pediatrics | NIH R21 2 years | A membrane fusion apparatus trailblazes measles virus spread in airway cells | |
David Weiss (Contact PI); Craig Ellermeier (MPI) | Microbiology | NIH R01 5 years | Defining the Structure and Function of a New Family of Peptidoglycan Crosslinking Enzymes | |
| Other Awards | ||||
| John Bernat | Pediatrics | Chiesi Farmaceutici S.p.A. 3 years | PegunigaLsidase Alfa in Patients from 2 Years to Less Than 18 Years of Age with Confirmed FabrY Disease | |
| Naomi Fei | Internal Medicine | Henlius USA Inc. 3 years | HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer | |
| Spyridon Fortis | Internal Medicine | GlaxoSmithKline, LLC 3 years | Anti-TSLP Antibody (GSK5784283) in Adults aged 18 to 75 years of age with Uncontrolled Asthma | |
| Muhammad Furqan | Internal Medicine | BioNTech SE 3 years | BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer | |
| Tara Graff | Internal Medicine | AbbVie, Inc. 3 years | Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORETMFL-2) | |
| Tara Graff | Internal Medicine | Merck Sharp & Dohme LLC 3 years | Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL) | |
| Tara Graff | Internal Medicine | Merck Sharp & Dohme LLC 3 years | A Randomized, Open-Label, Multicenter, Phase 2 Study Evaluating theEfficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP versus PolatuzumabVedotin plus R-CHP in Treatment-naive Participants with GCB Subtype of Diffuse Large B-Cell Lymphoma (DLBCL). | |
| Alan Gunderson | Internal Medicine | GigaGen Inc 3 years | GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants with Chronic Hepatitis B Virus Infection | |
| Henry Hoffman | Internal Medicine | MeiraGTX, LLC 3 years | Long-term Follow-up of AAV2-hAQP1 Gene Therapy in Participants with Radiation-Induced Late Xerostomia | |
| Matthew Krasowski | Pathology | CellaVision 2 years | CellaVision Clinical Studies of DI-90 | |
| Yusuf Menda | Radiology | Novartis Pharmaceuticals Corporation 4 years | [225Ac] Ac-ETN029 in patients with Advanced DLL3-expressing Solid Tumors | |
| Steven Moore | Pathology | Avidity Biosciences, Inc. 1 year | Avidity SOW 2 | |
| Kenneth Nepple | Urology | Pfizer Medical Grants & Partnerships (GMGP) 2 years | AI-Enhanced Quality Improvement to Optimize Genetic Testing in Advanced Prostate Cancer | |
| Dimah Saade | Pediatrics | REGENXBIO Inc. 3 years | Intravenous RGX-202 Gene Therapy in Males with Duchenne Muscular Dystrophy (DMD) | |
| Tomohiro Tanaka | Internal Medicine | Bluejay Therapeutics, Inc. 3 years | BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1) | |
| Hanna Zembrzuska | Internal Medicine | Zura Bio | Tibulizumab in Adults with Systemic Sclerosis | |
May 2025New Federal Awards | ||||
| Brad Amendt | Dental Research | NIH R56 1 year | Irx1 regulation of oral tissue repair and maintenance. | |
| Competitive Renewal | ||||
| Kris DeMali | Biochemistry & Molecular Biol | NIH R35 5 years | Molecular Mechanisms Underlying E-cadherin Mechanotransduction | |
| Quanhathai Kaewpoowat | Internal Medicine | US Department of Health & Human Services, Health Resources & Services Administration 3 years | OP EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE | |
| Other Awards | ||||
| Po Hein Ear | Surgery | Neuroendocrine Tumor Rsearch Foundation 2 years | Role of NRF2 in SBNETs and development of a novel inhibitor | |
| Mark Granner | Neurology | Neuron Therapeutics Inc 5 years | Inhibitory Interneurons (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Focal Seizures | |
| Douglas Laux | Internal Medicine | OncoResponse 3 years | OR502 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies | |
| Paul McCray | Pediatrics | Cystic Fibrosis Foundation 3 years | Optimizing Delivery of Prime Editors to Repair the CFTR F508del Mutation | |
| Mohamad Mokadem | Internal Medicine | Novo Nordisk Pharmaceuticals, Inc. 3 years | Testing peripheral nervous system as mediators of the metabolic effects of Monlunabant | |
| Eric Mou | Internal Medicine | Corvus Pharmaceuticals, Inc. 3 years | Soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL). | |
| Sneha Phadke | Internal Medicine | BeOne Medicines USA, Inc. 4 years | BGB-21447 (Bcl-2i) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer | |
| Edgar Samaniego | Neurology | Rapid Pulse 3 years | RapidPulseTM Aspiration System as Frontline Approach for Patients with Acute Ischemic Stroke due to Large Vessel Occlusions ("RapidPulse Pivotal Study") | |
| Hira Shaikh | Internal Medicine | AstraZeneca Pharmaceuticals LP 3 years | GC012F, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 andB-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma | |
| Patrick Sinn | Pediatrics | Cystic Fibrosis Foundation 3 years | Chimeric Adenoviral Vectors for Improved Base Editor Delivery to Primate Airways | |
| Lucy Wibbenmeyer | Surgery | Skingenix Inc. 3 years | Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns. | |
April 2025New Federal Awards | ||||
| Nagalakshmi Balasubramanian | Cardiothoracic Surgery | NIH K99 2 years | Alcohol-Induced Metabolome-Epigenome Dysfunction and Alzheimer's Disease Risk | |
| Ryan Boudreau | Internal Medicine | NIH R35 7 years | Genetic and Molecular Mechanisms of Heart Disease | |
| Amanda Dudek | Microbiology | NIH R00 3 years | Mechanisms that Enhance and Suppress HIV-1 Resistance in Gene Edited Primary Human Cells | |
| Amelia Hurley-Novatny | Orthopedic Surgery | NIH F30 4 years | Investigating the role of FGF21 in bone homeostasis in Duchenne Muscular Dystrophy | |
| Nicholas Schnicker | Medicine Administration | NIH S10 1 year | Acquisition of 200 kV Glacios Cryo-TEM at the University of Iowa | |
| Adele Stewart | Neuroscience & Pharmacology | NIH R21 2 years | Sex-biased, region-specific regulation of DA release and clearance | |
| Robert Weiss | Internal Medicine | NIH S10 1 year | High Resolution Research Ultrasound | |
| Competetive Renewal | ||||
| Kalpaj Parekh | Cardiothoracic Surgery | NIH R01 4 years | Pathogenesis of Airway Stem Cell Abnormalities in Obliterative Bronchiolitis | |
| Other Awards | ||||
| Caryn Berkowitz | Internal Medicine | CorMedix Inc. 3 years | DefenCath in Reducing Central Line-Associated Bloodstream Infections (CLABSIs) in Adult Participants Receiving Total Parental Nutrition (TPN) via Central Venous Catheter (CVC) | |
| Muhammad Furqan | Internal Medicine | Sanofi US Serices Inc. 3 years | SAR445877 administered as monotherapy or in combination with other anticancer therapies in adults with advanced solid tumors | |
| Tara Graff | Internal Medicine | AstraZenica LP 4 years | AZD0486 in Participants with Relapsed or Refractory B-cell Non-Hodgkins Lymphoma (SOUNDTRACK-B) | |
| James Holmes | Radiology | University of Virginia 1 year | Model Based Deep Learning Framework for Ultra-High Resolution Multi-Contrast MRI | |
| Asad Javed | Internal Medicine | IDEAYA Biosciences Inc. 3 years | IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC infusions | |
| Douglas Laux | Internal Medicine | Bicara Therapeutics 3 years | Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | |
| Vincent Magnotta | Radiology | University of Virginia 5 years | Fast Multi-dimensional Diffusion MRI with Sparse Sampling and Model-based Deep Learning Reconstruction | |
| John Rieth | Internal Medicine | SERVIER Bio-Innovation LLC 3 years | Ivosidenib in participants 18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen | |
| Edgar Samaniego | Neurology | Medtronic, Inc. 3 years | Clinical Investigation Plan of the Artisse Intrasaccular Device IDE | |
| Edgar Samaniego | Neurology | Terumo Neuro 4 years | Complex Aneurysm Registry (CAR) Real-World Evidence Data Collection for Intracranial Aneurysm Treatment Devices | |
| Antonio Sanchez | Internal Medicine | 89bio, Inc. 4 years | Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis (ENLIGHTEN-Fibrosis) | |
| Jennifer Streeter | Internal Medicine | Asklepios BioPharmaceutical, Inc. | GenePHIT | |
| Michael Tansey | Pediatrics | BioMarin Pharmaceutical, Inc. 3 years | Growth in Children with Idiopathic Short Stature | |
March 2025New Federal Awards | ||||
| Scott Moye-Rowley | Molecular Physiology & Biophysics | NIH R21 2 years | Nanobody-mediated proteolysis of Aspergillus fumigatus transcription factors in vitro and in vivo | |
Robert Mullins (Contact PI);
| Ophthalmology and Visual Sci | NIH R01 5 years | Editing AMD Risk Alleles in Human Cells | |
| Sarah Short | Internal Medicine | NIH R03 2 years | Epithelial specific roles for GPx1 in the intestinal microenvironment | |
| Long-Sheng Song | Internal Medicine | NIH R01 3 years | Junctophilin-1 in the heart | |
| Ian Thornell | Internal Medicine | NIH R01 4 years | Receptor-mediated Control of Pulmonary Ionocytes | |
| Other Awards | ||||
| Marcelo Correia | Internal Medicine | Novartis Pharmaceuticals Corporation | Evaluating INClisiran as a soLUtion to improve LDL-C management and cloSe care gaps in an Inclusive ASCVD and ASCVD risk equivalent population | |
| John Engelhardt | Anatomy and Cell Biology | Recode Therapeutics Inc. | Recode Scope of Work No 2 | |
| Umar Farooq | Internal Medicine | Celgene/ Bristol-Myers Squibb | JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL) (TRANSCEND FL) | |
| Andrew Feider | Anesthesia | Massachusetts General Hospital | Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep (MINDDS II) | |
| Alicia Gerke | Internal Medicine | Pulmovant, Inc. | Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease | |
| Michael Hummel | Radiology | ABK Biomedical USA, Inc. | Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) | |
| Yusuf Menda | Radiology | Perspective Therapeutics | [212Pb]VMT--NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors | |
| Kelly Mulfaul | Neuroscience & Pharmacology | Edward N. & Della L. Thome Memorial Foundation | Elucidating choroidal CCL5-CCR5 signaling to develop therapeutic targets for early AMD | |
| John Rieth | Internal Medicine | PHILOGEN S.p.A. | Doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin along as first-line therapy in patients with metastatic leiomyosarcoma | |
| Andrew Russo | Molecular Physiology & Biophys | Vedana Therapeutics, Inc. | Characterization of antibody and antibody-like molecules for their ability to reduce light-induced migraine-like phenotypes | |
| Hanna Zembrzuska | Internal Medicine | Cullinan Therapeutics, Inc | CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)", CLN-978-SL-101 | |
February 2025New Federal Awards | ||||
Budd Tucker (Contact PI); Edwin Stone (MPI); Robert Mullins (MPI) | Ophthalmology and Visual Sci | NIH R01 5 years | Non-destructive assessment of retinal differentiation capacity and developmental maturity | |
Mark Greiner (Contact PI): Aliasger Salem (MPI) | Ophthalmology and Visual Sci | NIH R01 5 years | Modulating Ferroptosis in Fuchs Endothelial Corneal Dystrophy | |
| Competitive Renewal | ||||
| Nandakumar Narayanan | Neurology | NIH R01 | Frontal Midline delta/theta rhythms and cognitive control in PD | |
| Other Awards | ||||
| Tara Graff | Internal Medicine | BeiGene Ltd. 3 years | Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | |
| Eric Mou | Internal Medicine | March Biosciences 6 years | MB-105 in patients with CD5 positive (CD5+) relapsed / refractory T-cell lymphoma (r/r TCL). | |
| Lama Noureddine | Internal Medicine | Alexion Pharmaceuticals, Inc. 3 years | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) | |
| Michael Tansey | Pediatrics | Novo Nordisk Pharmaceuticals, Inc. | Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c. 2.4 mg Once-weekly | |
| Michael Wall | Ophthalmology and Visual Sci | AbbVie, Inc. 1 year | AGN-193408 SR in Participants with Open-Angle Glaucoma or Ocular Hypertension | |
David Stolz (Contact PI); Daniel Cook, (MPI) | Internal Medicine | Cystic Fibrosis Foundation 3 years | Iowa CFF RDP Junior Faculty Recruitment Award | |
January 2025New Federal Awards | ||||
| Amy Ryan | Anatomy and Cell Biology | NSF 3 years | Collaborative Research: ENG-BIOTECH: Engineering Biomedical Systems to Investigate Extracellular Matrix Regulation of Airway Basal Cell Stemness and Differentiation | |
Punam Saha (Contact PI); Alejandro Comellas Freymond (MPI) | Radiology | NIH R21 2 years | Osteoporosis and Sarcopenia in COPD and CT-based Phenotypes | |
| Other Awards | ||||
| Paari Dominic | Internal Medicine | Texas Cardiac Arrhythmia Research Foundation | Safety and efficacy of pulsed-field ablation for atrial fibrillation in high versus low-volume ablation centers (SAFFICIENT) | |
| Naomi Fei | Internal Medicine | Planes Therapeutics, Inc. | PT886 followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction (GEJ), or Pancreatic Ductal AdEnocarcinomas of PT886, in Combination with either ChemotherApy, and/or the ChecKpoint Inhibitor Pembrolizumab. | |
| Henry Hoffman | Otolaryngology | RiboX Therapeutics, Ltd. (US) | RXRG001 to Parotid Gland(s) in Adults with Radiation-Induced Xerostomia and Hyposalivation | |
| Katherine Mathews | Pediatrics | Avidity Biosciences, Inc. | AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD) | |
Eric Taylor (Contact PI); Douglas Spitz (MPI) | Molecular Physiology | Nationwide Children's Hospital | Targeting Tubular Mitochondrial Superoxide Dismutation in Cisplatin Renal Repair | |
| Christopher Strouse | Internal Medicine | Janssen Research & Development, Inc 5 years | JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma | |
| Tracey Cho | Neurology | Sanofi US Services, Inc 5 years | Frexalimab (SAR441344) to Terifluomide (Aubagio) in Adult Participants with Relapsing Forms of Multiple Sclerosis | |
| Tracey Cho | Neurology | Sanofi US Services, Inc 5 years | Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis | |
| Katherine Mathews | Pediatrics | Avidity Biosciences, Inc 5 years | AOC 1044 Administered Intravenously to Healthy Adults | |
| Val Sheffield | Pediatrics | CRISPR Therapeutics, Inc 2 years | MYOC gene editing for Myocilin Associated Glaucoma | |